Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

H. Jean KhouryEmory University School of Medicine, Atlanta, GA, USACorrespondence[email protected]

Jorge CortesUniversity of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Michele BaccaraniInstitute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy

Meir WetzlerRoswell Park Cancer Institute, Buffalo, NY, USA

Tamas MassziSt. István and St. László Hospital, Budapest, Hungary

Raghunadharao DigumartiNizam's Institute of Medical Sciences, Hyderabad, India

Adam CraigChemGenex Pharmaceuticals, a wholly owned subsidiary of Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA

Annie-Claude BenichouChemGenex Pharmaceuticals, a wholly owned subsidiary of Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA

Luke AkardIndiana Blood and Marrow Transplantation Franciscan Alliance, Indianapolis, IN, USA

Your download is now in progress and you may close this window